Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
Open Access
- 19 July 2016
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 16 (1) , 109
Abstract
Alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, is licensed in Europe since October 2013 as treatment for adult patients with active relapsing-remitting multiple sclerosis (RRMS). In three randomized, rater-blinded active comparator clinical trials studies, alemtuzumab administered in two annual courses, had superior efficacy as compared to subcutaneous interferon beta-1a, and durable efficacy over 5 years in an extension study with a manageable safety profile in RRMS patients. Data on the utilization and the outcomes of alemtuzumab under clinical practice conditions are limited. Here we describe the rationale, design and methods of the TREAT-MS study (non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing-remitting MS). TREAT-MS is a prospective, multicenter, non-interventional, long-term study to collect data on safety, effectiveness, quality of life, cognition and other aspects from 3200 RRMS patients treated with alemtuzumab under the conditions of real-world clinical practice in Germany. As non-interventional trial in Germany.Keywords
This publication has 59 references indexed in Scilit:
- Reprogramming the immune repertoire with alemtuzumab in MSNature Reviews Neurology, 2013
- Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical TrialNeurology, 2012
- A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosisBlood, 2011
- Multiple-Sklerose-Dokumentationssystem 3DDer Nervenarzt, 2011
- International Development of the Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS)Value in Health, 2010
- The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)Multiple Sclerosis Journal, 2009
- A single European currency for EQ-5D health statesThe European Journal of Health Economics, 2003
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993
- Rating neurologic impairment in multiple sclerosisNeurology, 1983